Literature DB >> 6224624

Moxalactam kinetics during chronic ambulatory peritoneal dialysis.

E Singlas, H F Boutron, H Merdjan, J F Brocard, M Pocheville, D Fries.   

Abstract

Moxalactam kinetics in renal failure were followed in eight patients undergoing chronic ambulatory peritoneal dialysis (CAPD) after a single 1-gm IV infusion. Elimination t 1/2 was 16.7 +/- 2.1 hr, with an apparent volume of distribution of 0.21 +/- 0.01 l/kg and plasma clearance of 10.6 +/- 2 ml/min. In 24 hr, 17.4 +/- 3.1% of the dose was present in the dialysis fluids, and 14.6 +/- 5.7% was excreted in the urine. Renal and peritoneal clearance values were thus 2.3 +/- 1.1 and 2.7 +/- 0.5 ml/min. Peritoneal concentrations were high (22.7 +/- 2.2 micrograms/ml). A recommended dosage schedule is proposed on the basis of moxalactam kinetics during CAPD.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224624     DOI: 10.1038/clpt.1983.187

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

2.  Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Authors:  T E Jones; R W Milne; Y Mudaliar; L N Sansom
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 3.  Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.

Authors:  R Janknegt; C H Koks
Journal:  Pharm Weekbl Sci       Date:  1984-12-14

4.  Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.

Authors:  P Somani; E H Freimer; M L Gross; J T Higgins
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis.

Authors:  E Singlas; A M Taburet; I Landru; H Albin; J P Ryckelinck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.

Authors:  H Merdjan; A Baumelou; B Diquet; O Chick; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.